DexTech Medical AB (XSAT:DEX) Total Assets: kr20.68 Mil (As of Mar. 2026)


XSAT:DEX DexTech Medical AB XSAT:DEX
17 GF Score
Price kr10.20
! 2 Warning Signs
View Full Analysis

What is DexTech Medical AB Total Assets?

DexTech Medical AB XSAT:DEX -0.49% 17 Total Assets is kr20.68 Mil as of Mar. 2026. GuruFocus rates XSAT:DEX with a GF Score™ of 17/100. The stock has 2 warning signs investors should review.

DexTech Medical AB's Total Assets for the quarter that ended in Mar. 2026 was kr20.68 Mil.

During the past 12 months, DexTech Medical AB's average Total Assets Growth Rate was -3.60% per year. During the past 3 years, the average Total Assets Growth Rate was 36.20% per year. During the past 5 years, the average Total Assets Growth Rate was 18.80% per year. During the past 10 years, the average Total Assets Growth Rate was -6.80% per year.

During the past 13 years, DexTech Medical AB's highest 3-Year average Total Assets Growth Rate was 45.10%. The lowest was -43.20%. And the median was 13.05%.

Total Assets is connected with ROA %. DexTech Medical AB's annualized ROA % for the quarter that ended in Mar. 2026 was -32.19%. Total Assets is also linked to Revenue through Asset Turnover. DexTech Medical AB's Asset Turnover for the quarter that ended in Mar. 2026 was 0.00.

DexTech Medical AB  (XSAT:DEX) Total Assets Explanation

Total Assets is connected with ROA %.

DexTech Medical AB's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-6.92/( (22.315+20.679)/ 2 )
=-6.92/21.497
=-32.19 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

DexTech Medical AB's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0/( (22.315+20.679)/ 2 )
=0/21.497
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

DexTech Medical AB Total Assets Related Terms

DexTech Medical AB Total Assets Historical Data

* Premium members only.

The historical data trend for DexTech Medical AB's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DexTech Medical AB Total Assets Chart

DexTech Medical AB Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.23 39.59 35.03 30.59 25.10

DexTech Medical AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.55 25.10 24.25 22.32 20.68
XSAT:DEX
17GF Score
DexTech Medical AB XSAT:DEX
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DexTech Medical AB Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

DexTech Medical AB's Total Assets for the fiscal year that ended in Jun. 2025 is calculated as

Total Assets=Total Equity (A: Jun. 2025 )+Total Liabilities (A: Jun. 2025 )
=24.763+0.337
=25.10

DexTech Medical AB's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=20.144+0.535
=20.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of kr20.68 Mil mean?
DexTech Medical AB (XSAT:DEX) has a Total Assets of kr20.68 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on DexTech Medical AB and its competitors.
Is DexTech Medical AB's Total Assets too high?
DexTech Medical AB's current Total Assets is kr20.68 Mil. Overall, DexTech Medical AB has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does DexTech Medical AB's Total Assets compare to VRTX and REGN?
DexTech Medical AB's Total Assets of kr20.68 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on DexTech Medical AB and its competitors. DexTech Medical AB's current Total Assets is kr20.68 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DexTech Medical AB stock overvalued right now?
DexTech Medical AB (XSAT:DEX) has a current Total Assets of kr20.68 Mil. The current Total Assets is kr20.68 Mil. DexTech Medical AB's overall GF Score™ is 17/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For DexTech Medical AB (XSAT:DEX), the current Total Assets is kr20.68 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DexTech Medical AB Business Description

Address Dag Hammarskjolds Vag 34A, Uppsala, SWE, 752 37
DexTech Medical AB is a Swedish research company specializing in drug development for urological oncology, with a prominent focus on prostate cancer. The company develops drug candidates using a proprietary carbohydrate platform, advancing treatments aimed at castration-resistant prostate cancer and related conditions. Its operations center on research, development, and licensing of these drug candidates. It has four drug candidates: OsteoDex, SomaDex, PSMA-binding conjugates, and GuaDex.
17GF Score

Get the complete analysis for XSAT:DEX

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr10.20
Price